CIC-DUX4 sarcoma is a rare subtype of sarcoma characterized by a devastating prognosis and resistance to conventional therapeutic strategies. So far, only few models of the disease have been reported, and its biological mechanisms remain to be elucidated. We established mosaic transgenic zebrafish expressing the human CIC-DUX4 fusion under the control of the β-actin promoter. CIC-DUX4 transgenic fish rapidly developed aggressive soft tissue tumors with a high penetrance.
Introduction
CIC-DUX4 sarcomas (CDS) consist of a group of small round cell sarcomas affecting mostly young adults and characterized by the development of aggressive soft tissue tumors with devastating prognosis and resistance to conventional therapeutic strategies (1) . From a pathological point of view, CDS present with small to medium-sized, round to ovoid undifferentiated tumor cells, often organized in nodular patterns, and showing variable expression of CD99 (2) . Due to their clinical and pathological partial overlap with Ewing sarcomas, CDS have long been classified as "Ewing-like sarcomas" since no evidence of FET-ETS fusion gene could be identified in those tumors. CIC-DUX4 is a fusion of the transcriptional repressor CIC with the double homeobox protein DUX4. CIC-DUX4 fusions were first identified in 2006, and later shown to result either from a t(4;19)(q35;q13) or a t(10;19)(q26.3;q13) translocation (3, 4) , with the DUX4 gene being located both on chromosome 4 and chromosome 10 subtelomeric regions. The resulting CIC-DUX4 fusion protein retains most of the wild-type CIC, with its DNA-binding domain fused to the C-terminal portion of DUX4, and it has thus been hypothesized that the chimeric protein would act as an aberrant transcription factor.
Additional studies have shown that CDS are biologically distinct from classical FET-ETS-positive Ewing sarcomas, and characterized by a specific transcriptomic signature (5) which includes expression of the PEA3 transcription factors ETV4, ETV5 and ETV1 (3, 6) . ETV4 expression has recently been recognized as a specific diagnostic marker for the identification of CIC-rearranged sarcomas in clinical specimens (7, 8) . So far, the mechanisms by which CIC-DUX4 regulates gene expression to promote oncogenesis are still poorly understood, mostly due to the rarity of the disease and the lack of appropriate in vitro and in vivo models. CIC-DUX4 was shown to be able to bind the promoters of PEA3 transcription factors and activate their expression in vitro (3) . The oncogenic properties of the fusion protein have been more recently studied in an ex vivo model, showing that CIC-DUX4 expression could transform mouse mesenchymal progenitor cells and drive the development of small round cell tumors in mice (9) . However, the cell of origin of the tumor is still unknown which has hindered the development of robust animal models, and the role of ETV4 overexpression and its contribution in CIC-DUX4-mediated oncogenesis remains to be elucidated.
We report here the successful generation of the first transgenic animal model of CDS. By creating mosaic transgenic animals expressing human CIC-DUX4 under the control of the β-actin ubiquitous promoter, we show that CIC-DUX4 expression is sufficient to induce the development of small round cell sarcomas in adult zebrafish with a high penetrance. Zebrafish tumors were similar to human CDS both from pathological and biological points of view, with the expression of a common set of genes including Ets transcription factors. By using an etv4-deficient fish strain, we demonstrated that Etv4 is crucial to the development of CDS in zebrafish, since etv4-deficiency abrogated tumor development. This robust model highlights for the first time the oncogenic properties of CIC-DUX4 in vivo and leads the way to the design of new therapeutic strategies.
Results

CIC-DUX4 is a potent oncogene in transgenic zebrafish
To study the oncogenic properties of CIC-DUX4 in vivo, we cloned the human CIC-DUX4 fusion together with the GFP-2A fluorescent reporter under the control of the β-actin ubiquitous promoter into the Tol2 transposon system ( Figure 1A) . The transgene was injected in one-cell-staged wildtype zebrafish embryos to be integrated in the genome in a stable mosaic manner. The embryos were raised to adulthood and monitored for tumor growth. CIC-DUX4 transgenic zebrafish showed the development of aggressive tumors, starting around 50 days post-fertilization (dpf) and affecting more than 30% of injected individuals by 90 dpf, whereas no tumor was observed in control animals injected with GFP-2A alone ( Figure 1B ). Tumors were mostly developing rapidly from muscle, growing either in the perimuscular tissues or as exophytic masses ( Figure 1C ), or in the head and brain area ( Figure 1D ). Pathological examination of tumors revealed two main histotypes. Most tumors developing from muscles showed the presence of proliferative small round tumor cells packed in highly cellular lesions and lacking any specific line of differentiation ( Figure 1E ). In contrast, tumors developing in the head presented rather with more disperse tumor cells surrounded by a frequent myxoid stroma and exhibiting neural-like differentiation ( Figure 1F ). The latter tumors were often large and infiltrated adjacent tissues, which made it difficult to determine whether they originated from the brain or from facial structures.
CIC-DUX4 zebrafish tumors are biologically homogeneous
CIC-DUX4 may act either as an oncogene, through a gain-of-function effect via aberrant transactivation of target genes or, and non-exclusively, through a dominant negative effect on CIC's repressor activity. To identify the genes regulated by CIC-DUX4 in zebrafish tumors, we performed whole transcriptomic analyses of 12 different CIC-DUX4 fish tumors by RNAseq. The transcriptomic signatures were compared to normal muscle from adult fish, and to other fish tumors including four malignant peripheral nerve sheath tumors (arising spontaneously in tp53 M214K/M214K mutant fish) and six EWSR1-FLI1-driven tumors from our previously-developed zebrafish model of Ewing sarcoma (10) . Unsupervised clustering revealed that the zebrafish CIC-DUX4 form a single cluster of tumors that can be further refined in two subgoups, consistent with pathological observations of the two different histological subtypes previously observed (Figure 2A,B ).
Principal component analysis of the transcriptomic data similarly revealed two subgroups within the CIC-DUX4 cluster, corresponding to the histologic variants ( Figure 2C ).
CIC-DUX4 zebrafish tumors show biological overlap with human tumors and cell lines and overexpress orthologs of the ETS transcription factors ETV4, ETV5 and ETV1
To study the similarity of CIC-DUX4 zebrafish tumors to the human malignancies, we next compared the transcriptomic profiles of CIC-DUX4 fish tumors with those of human primary CDS.
We first identified 1412 genes differentially expressed in fish CDS as compared to EF1 and MPNST tumors ( Supplementary Table S2 ), among which 892 were up-regulated and with a defined human orthologue. Matching these 892 genes to the 595 genes specifically expressed in human CDS (6) and having a zebrafish orthologue, highlighted 97 genes commonly up-regulated in both species (Fisher exact test P-value < 1e -12 ).
To further refine the comparison of fish and human tumors, we compared the expression profiles of the CIC-DUX4 fish tumors with the genes regulated by CIC-DUX4 in the IB120 cell line. The IB120 cell line is derived from a primary human CIC-DUX4 tumor. CIC-DUX4 expression was inhibited in vitro by siRNA, and Affymetrix microarrays were performed on siCIC-DUX4 IB120 and siControl IB120 cells to identify the genes regulated by the fusion oncogene ( Supplementary   Table S1 ). Gene Set Enrichment Analyses showed a significant concordance between the genes up-regulated in the CIC-DUX4 zebrafish tumors as compared to normal muscle and the genes upregulated by CIC-DUX4 in the IB120 cells (genes down-regulated by CIC-DUX4 inhibition) ( Figure 3A ). Reciprocally, genes down-regulated in fish tumors were significantly concordant with the genes down-regulated by CIC-DUX4 (up-regulated upon CIC-DUX4 inhibition) ( Figure 3B) , showing that the fusion oncogene similarly regulates common targets in fish tumors and in the human primary tumor-derived cell line.
Comparing the 97 genes commonly up-regulated in fish and human tumors with the 636 genes upregulated by CIC-DUX4 in the IB120 cell line ( Supplementary Table S1 ) and having a known zebrafish orthologue, we identified 26 genes (exact Fisher-test P-value: 4e-9) that were overexpressed in all three models (Table 1) , which included the PEA3 transcription factors ETV4 and ETV5.
Etv4 expression is necessary for CIC-DUX4 mediated oncogenesis in vivo ETV4 overexpression has already been well-documented in CDS; however its role in CICmediated sarcomagenesis has never been studied in vivo so far. To address this question, we took benefit of an etv4-deficient fish strain, in which etv4 has been knocked-out by CRISPR-Cas9 technology (etv4-/-). Human CIC-DUX4 was integrated in the genome of wildtype or etv4-/-fish using the Tol2 transposon system to generate mosaic transgenic animals, and adult fish were monitored for tumor development. As previously shown, CIC-DUX4-driven tumor development was highly penetrant in the wild-type background with more than 30% of fish developing tumors by 75 dpf. In contrast, etv4 deficiency significantly impaired tumor formation with less than 10% of etv4 -/fish developing tumors in the same time-frame (Mantel-Cox Log-rank test P-value: 0.02) ( Figure 4) , showing that Etv4 is major mediator of CIC-DUX4-induced sarcomagenesis in vivo.
Discussion
Since the first identification of CIC-DUX4 fusion transcript in two human small round cell sarcomas in 2006, more than 150 different cases have been reported in the literature (1, 4, 11) . The advances in the techniques of molecular biology and the identification of specific markers to aid in pathological diagnosis have led to a significant increase in the number of reported cases (8, (12) (13) (14) , and it is now acknowledged that CDS represents the most frequent subtype of the previously-called Our model is the first transgenic animal model of CDS. We demonstrated that CIC-DUX4 expression is sufficient to drive the development of tumors in transgenic zebrafish with a remarkable penetrance for a mosaic model. Moreover, the use of a ubiquitous promoter was chosen due to the fact that CDS cell of origin is unknown; thus the expression of the oncogene under the control of an appropriate tissue specific promoter might even increase tumor penetrance.
Transgenic zebrafish tumors arose mainly from muscle or from the head with a very short latency and developed as undifferentiated aggressive malignancies with invasion of local anatomical structures. This clinical and pathological behavior is similar to human CDS, with most tumors developing from limbs or abdominal wall muscles and growing extensively. In our model, tumors arising from the head or the brain presented a rather different pathological aspect, with increased neural differentiation and myxoid stroma. Whether the pathological differences observed within fish tumors reflect the cell of origin of the disease remains to be further studied. Of note, head and neck CDS are not uncommon in humans (18), and several cases of CDS arising from the brain have been reported, sometimes with atypical histology (19, 20) . Moreover, the related CIC-NUTM1 fusion is a recurrent genetic lesion in a subset of central nervous system Primitive Neuroectodermal Tumors (CNS-PNETs) (21, 22) .
The overexpression of Ets transcription factors has long been identified as a hallmark of CDS, and ETV4 immunostaining is even used in clinical practice to help diagnosis (7) . PEA3 transcription factors ETV1, ETV4 and ETV5 are expressed in numerous organs during embryonic development and in adults, and are thought to play various physiological functions involved in morphogenesis of limbs and kidneys, and in motor coordination (23) . In oncogenesis, EWSR1-ETV1 and EWSR1-ETV4 fusions have been reported as rare events in classical Ewing sarcoma (24) , and TMPRSS2 fusions with either ETV1, ETV4 or ETV5 are also observed in prostate carcinoma (25) . Moreover, ETV4 overexpression has been identified as an independent factor of poor prognosis in various types of malignancies, including breast, gastric, colorectal, and lung carcinoma (23) . Under physiological conditions, CIC transcriptionally represses the expression of ETV4 and downstream targets, including genes involved in extracellular matrix remodeling and cell proliferation (26) . Importantly, oligodendroglioma harboring CIC inactivating mutations present ETV4 overexpression and are characterized by an aggressive behavior (27) . And inactivation of CIC in lung and gastric carcinoma result in ETV4 overexpression and increased risk of metastasis (28) .
Thus, whether ETV4 overexpression in CDS is the direct consequence of CIC-DUX4
transcriptional activation or might result from the loss of function of wild-type CIC remains to be further studied in vivo. We showed however that Etv4 is crucial to tumor development in our model, since CIC-DUX4-mediated tumor growth was abrogated in Etv4-deficient zebrafish. This finding is of major interest for the clinical management of CDS, for which conventional therapies are poorly effective, especially as strategies to pharmacologically target Ets transcription factors are being developed. We thus believe that this first in vivo model of CDS will be of particular interest to further study the biological mechanisms of the disease and will constitute a major tool for the elaboration of new targeted therapies for the human disease.
Methods
Zebrafish husbandry
Danio rerio were maintained in an aquatics facility according to industry standards. Vertebrate animal work was carried out according to protocols approved by the Institutional Animal Care and Use Committee at UT Southwestern, an AALAC-accredited institution committee. Zebrafish were originally obtained from the Zebrafish International Resource Center (https://zebrafish.org). The wildtype lines used were AB/TL hybrids. The tp53 mutant line, tp53 zdf1 , was a kind gift from Tom Look (29) . The etv4 mutant line was generated in the wildtype NHGRI-1 strain.
Generation of a Tol2 enabled CIC-DUX4 expression construct
The human CIC-DUX4 coding sequence was sub-cloned directly from a patient tumor and integrated into the Gateway expression system (Thermo) by adding 5' and 3' ATT sites (attb2r/attb3) with primers and high-fidelity PCR. Purified PCR products were cloned into a 3' entry clone as previously described (30) . The tol2 kit β-actin promoter, 3' SV40 late poly A signal construct, and pDestTol2pA2 destination vector were used for construct generation and expression in zebrafish (31) . The GFP viral 2A sequence was a kind gift from Steven Leach (32) , and was previously sub-cloned into a middle entry Gateway expression system (33) . Tol2 mRNA was synthesized from pCS2FA-transposase from Koichi Kawakami (34) . The constructs utilized in this study include: β-actin-GFP2A-pA and β-actin-GFP2A-CICDUX4.
CIC-DUX4 integration into zebrafish embryos and characterization of tumor incidence
Zebrafish were injected at the single cell stage with injection mixes containing 50ng/µL Tol2 transposase mRNA, 40ng/µL of BetaActin-GFP2A-pA or BetaActin-GFP2A-CICDUX4 Tol2 enabled plasmid, 0.1% phenol red, and 0.3X Danieau's buffer. The same microinjection needle was utilized to inject wildtype and etv4-/-mutant zebrafish to compare CIC-DUX4 tumorigenic capacity. Zebrafish presenting with tumors were screened under the fluorescent microscope to determine if they were GFP positive, were collected, and the presence of malignancies confirmed by H&E staining and visual review by a pathologist.
Zebrafish tumor collection and downstream processing of RNA and histology
Zebrafish with tumors were euthanized and screened under a Nikon SMZ25 fluorescent stereomicroscope to detect GFP expression indicative of CIC-DUX4 expression. Fresh GFP+ tumor tissue was resected and snap frozen in liquid nitrogen. Total RNA was isolated from zebrafish using the TRIzol reagent kit (Invitrogen) and was utilized for RNAseq. The remaining tumor specimen was fixed in 4% paraformaldehyde/1XPBS for 48 hours at 4°C (Fisher). Samples were then de-calcified in 0.5M EDTA for 3-5 days and mounted in paraffin blocks for microtome sectioning. Hematoxylin and eosin (H&E) staining was performed on de-paraffinized slides.
Generation of etv4 mutant allele by CRISPR-Cas9
A single-stranded guide RNA and Cas9 mRNA were prepared as described (35) . The guide RNA was designed to target the second of exon of etv4 (5'-aattaatacgactcactataGGACGCAGAATTACCCCCTCgttttagagctagaaatagc-3'; T7 promoter underlined, etv4 target sequence uppercase, overlap to sgRNA scaffold oligo italicized). An injection solution was prepared with 12ng/µL of guide RNA, 30ng/µL Cas9 mRNA, 300mM KCl, and 0.1% phenol red. 2nL of injection solution was injected into the yolk of 1-cell stage zebrafish embryos. Cutting efficiency of the guide RNA was determined by High Resolution Melt Analysis (HRMA) at 24hpf with 8 injected embryos and 8 uninjected controls using the primers etv4-Fwd (5'-AGAGGTCGCAAGGAAATGGGC-3') and etv4-Rev (5'-AACTTGCTTGTTATTTTACCTTCAGAT-3') (36) . Sperm from injected males was screened by HRMA for germline transmission of etv4 alleles with indels. A 14bp frameshiftcausing deletion was identified in an injected male founder by Sanger sequencing of genomic DNA. The frameshift allele was confirmed by sequencing an etv4 cDNA from outcrossed embryos.
Cell line and reagents :
IB120 cells are a kind gift from Dr. Jean-Michel Coindre and Frederic Chibon (Institut Bergonié, Bordeaux, France) and were derived from a primary tumor harboring the CIC-DUX4 fusion. IB120 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Life Technologies, Saint Aubin) supplemented with 10% fetal calf serum (Eurobio, Courtaboeuf) and 50U/50µg penicillin/streptomycin (Life Technologies). FlexiTube siRNAs against DUX4 and control siRNA were purchased from Qiagen (Courtaboeuf). Transfections of siRNAs were performed using the Lipofectamine RNAiMAX transfection reagent (Life Technologies). 150 000 cells were seeded in 6-well plated in 2 mL of antibiotics-free medium and transfected 24 hours later with 20nM of total siRNA. RNA extraction was performed 48 hours after transfection with RNA extraction kits (Macherey) following manufacturer's instructions and then used for Affymetrix microarrays.
Microarray:
HG-U133-Plus2 GeneChip microarrays were performed by the Affymetrix platform of the Institut Curie according to the Affymetrix GeneChip Expression Analysis Technical Manual. Expression profiles were normalized using the gcrma package version 2.34.0 in the R 3.0.2 environment (R Development Core Team, 2012) with Brainarray Entrez gene CDF v18. Quality assessment was based on relative log expression and normalized unscaled standard errors. Raw data were deposited on the Gene expression Omnibus database, as part of the GSE60740 dataset: (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60740).
Paired-end RNA sequencing. Library constructions were performed following the TruSeq Stranded mRNA LS protocol (Illumina, San Diego, CA, USA) and sequencing was performed on HiSeq 2500 (50nt paired-end) Illumina sequencing machines, with an average of 30 million of reads per sample, by the NGS platform of the Institut Curie. FASTQ files will be deposited on the Gene expression Omnibus database. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Differential expression analysis were performed using Welsh t-tests and the associated P-values were corrected by the Bonferroni procedure. Only the genes with a Bonferroni corrected P-value under 0.05 and an absolute fold change above 2 were further considered. Orthologues were identified using a combination of annotations from Ensembl (www.ensembl.org) and the Zebrafish Information Network (https://zfin.org) databases. 
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